Black Diamond Therapeutics (BDTX) Free Cash Flow (2019 - 2026)
Black Diamond Therapeutics (BDTX) free cash flow from Mar 31, 2019 to Mar 31, 2026. The TTM Black Diamond Therapeutics (BDTX) free cash flow is -$34M. You can adjust inflation or export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Annual Free Cash Flow
Quarterly Free Cash Flow
Black Diamond Therapeutics (BDTX) Free Cash Flow CAGR table
| Period | CAGR |
|---|---|
| 3 Years TTM | -23.74% |
| 5 Years TTM | -12.27% |
| All Time TTM | +2.63% |
Annual Free Cash Flow change of Black Diamond Therapeutics (BDTX)
| Year | Free Cash Flow | Change |
|---|---|---|
| 2026 | -$10M | -134.55% |
| 2025 | $30M | -147.53% |
| 2024 | -$62M | -6.67% |
| 2023 | -$67M | -21.72% |
| 2022 | -$85M | -17.10% |
| 2021 | -$103M | +96.71% |
| 2020 | -$52M | +111.79% |
| 2019 | -$25M | +189.45% |
| 2018 | -$8.53M | N/A |
Comparison Black Diamond Therapeutics (BDTX) five years free cash flow CAGR with competitors
Black Diamond Therapeutics (BDTX) five years free cash flow CAGR is -12.27%.